SOURCE: Bio-Rad Laboratories

August 27, 2007 08:00 ET

Bio-Rad Launches Syphilis IgG Kit for Use on Its BioPlex 2200 System

Novel Automated Multiplexing Technology Streamlines Syphilis Testing and Maximizes Laboratory Efficiency

HERCULES, CA--(Marketwire - August 27, 2007) - Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has launched a test for syphilis for use on its BioPlex® 2200 system, a revolutionary diagnostic platform that employs multiplexing technology to analyze multiple disease markers from a single patient sample.

The BioPlex 2200 Syphilis IgG kit simultaneously detects three of the most clinically relevant Treponema pallidum (the bacteria that causes syphilis) antibodies using recombinant proteins in a multiplex format. The Syphilis IgG kit can be used as a diagnostic clinical screen for past or present syphilis infection or as a diagnostic confirmatory test.

"The release of the Syphilis IgG kit is another example of Bio-Rad's continued commitment to providing valuable tools that enable laboratories to improve testing methods, maximize efficiencies, and lower costs," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics.

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system that provides clinical laboratories with the technology to rapidly process or "multiplex" multiple individual tests, which are traditionally processed separately, using a single small volume patient sample.

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

Contact Information

  • For more information contact:
    Tina Cuccia
    Corporate Communications Manager
    Bio-Rad Laboratories, Inc.
    510-724-7000
    Email Contact